-
Welsh rugby great North to hang up his boots
-
Much-needed rains revive Iraq's fabled Mesopotamian Marshes
-
French teen in straw licking case allowed to leave Singapore
-
EU chief says Kremlin imposing 'digital Iron Curtain' on Russians
-
South Korean court hikes ex-president's sentence for obstructing justice
-
Adidas reports higher profits but warns of 'volatile' climate
-
TotalEnergies first-quarter profits surge amid Middle East war
-
Sri Lanka government 'temporarily' takes over cricket board
-
EU finds Meta failing to keep under-13s off Facebook, Instagram
-
King Charles to stress UK-US cultural, trade ties in New York
-
US judge orders Purdue Pharma to pay billions ahead of bankruptcy
-
'Jurassic Park' star Sam Neill says cancer-free after gene therapy
-
US opioid crisis victims testify at emotional Purdue Pharma hearing
-
Australian climber on record sea-to-summit Everest bid
-
Indian opposition slams Nicobar megaport plan as 'destruction'
-
Pentagon chief to testify on Iran war, peace efforts stall
-
Anxiety, resentment around AI spur violence against tech's figureheads
-
Mercedes-Benz profit slides amid cutthroat Chinese market
-
Hungary's Magyar to push post-Orban EU reset on Brussels visit
-
Going online helps Pakistan's women doctors back to work
-
Wembanyama's Spurs advance in NBA playoffs, 76ers stay alive
-
Tropical forest loss eases after record year: researchers
-
Tigres edges Nashville in CONCACAF Champions Cup first leg
-
New Zealand officials reject statue remembering Japan's sex slaves
-
King Charles, Trump toast ties despite Iran tensions
-
Japan cleaner goes viral with spa-like service for plushies
-
What we learned from cycling's Spring Classics
-
Villa, Forest revive European glory days in semi-final showdown
-
Remarkable, ramshackle Rayo chasing Conference League dream amid chaos
-
Unbeaten records on the line for Inoue-Nakatani superfight in Tokyo
-
Cheaper, cleaner electric trucks overhaul China's logistics
-
Stocks swing, oil edges up with Iran war peace talks stalled
-
Europe climate report signals rising extremes
-
Sexual violence in Sudan triggers mental health crisis: UN
-
The loyal, lonely keepers of Sudan's pyramids
-
'Final mission': NZ name star trio for T20 World Cup defence
-
Embiid-led 76ers beat Boston to avoid NBA playoff exit
-
An experimental cafe run by AI opens in Stockholm
-
Exiting fossil fuels key to energy security: nations at Colombia talks
-
Jerome Powell: Fed chair who stood up to Trump set to finish tenure on top
-
All eyes on Powell with US Fed expected to hold rates steady
-
Pentagon makes deal to expand use of Google AI: reports
-
King Charles urges US-UK reset in speech to Trump
-
France unveils plan to ditch all fossil fuels by 2050
-
World Cup to get cash boost as FIFA unveils red card crackdown
-
LIV Golf postpones New Orleans event
-
Luis Enrique predicts more thrills in return leg after PSG beat Bayern in classic
-
AI fakes of accused US press gala gunman flood social media
-
Ex-FBI chief Comey charged with threatening Trump's life in Instagram post
-
PSG edge Bayern in nine-goal Champions League semi-final epic
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
F.Moura--PC